Preparing for the new realities

COVID has led to virtualization of a significant part of patient journey. There are several opportunities, along with a need to address certain challenges:

  • How will hospitals change?
  • Telemedicine and digital tools (e.g. wearables, mobile apps, sensors, etc., for remote diagnosis, patient monitoring, disease management, etc.) can play significant role in improving access to healthcare while reducing cost: examples of successful telemedicine practice and virtual tools for health management, and diagnosis & disease management
  • Regulatory frameworks and policies are required to achieve telemedicine potential, e.g. for ethical telemedicine practice, a platform for securely sharing data, etc.
  • National Digital Health Mission is a great platform for India to achieve its 'connected healthcare vision'
  • Hospitals need to evolve into Smart Hospitals to provide connected care experience to the patients
  • Pharma companies can also play a critical role by providing virtual services and integrating with the virtual patient journey


  • Mr. Arnaud Bernaert, Head of Global Health and Healthcare, World Economic Forum
  • Ms. Carmen (C.F.M.) van Vilsteren, Chair Top Sector Life Sciences & Health, Health Holland
  • Ms. Sangita Reddy, Joint MD, Apollo Hospitals
  • Ms. Debjani Ghosh, President, NASSCOM
  • Mr. Kaivaan Movdawalla, Partner, Healthcare, EY India


  • Ms. Rhythma Kaul, Health Editor, Hindustan Times

India’s current position and future potential

The focus of the session will be to explore India's potential and key steps/actions to become the future global innovative vaccines provider:

  • how is India enabling the fulfilment of the global COVID vaccination goal?
  • what vaccination coverage have we achieved and planned for India (plan to produce and deliver to the masses)?
  • what is India's potential as global provider of innovative vaccines in the future?
  • what steps should be taken to achieve the potential soon?


  • Dr. Soumya Swaminathan, Chief Scientist, World Health Organization
  • Dr. Nivedita Gupta, Scientist-F (Deputy Director General, Indian Council of Medical Research(ICMR))
  • Dr. Robin Nandy, Principal Advisor & Chief of Immunizations, UNICEF
  • Dr. Jerome H. Kim, Director General, International Vaccine Institute (IVI), South Korea
  • Dr. Krishna Ella, CMD, Bharat Biotech International Ltd.
  • Ms. Mahima Datla, Managing Director, Biological E


  • Ms. Divya Rajagopal, Senior Assistant Editor, The Economic Times (ET)

The earlier fears and theories for need to prepare for future pandemic came alive when the COVID-19 took the entire world by surprise in early 2020. The pandemic brought to fore several important areas that need immediate attention. The session will provide answers to the following:

  • What are the learnings from COVID-19 to develop robust healthcare systems and for responding better for the next pandemic?
  • What investments need to be made today and in which areas to prevent future pandemics? What efforts are already in place or in pipeline in this direction?
  • What actions should be taken to effectively resume delivery of other health care services, such as chronic disease diagnosis and treatment, elective surgeries, etc. while managing the COVID-19 pandemic burden?

Special Address: Dr. Trevor Mundel, President (Global Health), Bill and Melinda Gates Foundation


  • Dr. Renu Swarup, Secretary to Government of India, Department of Biotechnology
  • Dr. V.G. Somani, Drugs Controller General (India), Central Drugs Standard Control Organization
  • Dr. Richard Hatchett, Chief Executive Officer, CEPI
  • Dr. Peter Piot, Director, London School of Hygiene and Tropical Medicine
  • Dr. Naresh Trehan, Chairman and Managing Director, Medanta Hospital


  • Mr. Vikas Dandekar, Editor (Pharma and Healthcare), ET Prime

Self-reliance to becoming preferred suppliers

The entire world struggled with the supply chain disruption during the pandemic. The session will deliberate on the following topics:

  • how did the world dynamics change?
  • what has been India's position?
  • What efforts have been made to achieve supply chain resilience globally and what were some of the challenges (e.g. higher costs)?
  • what strategies have been adopted by the Indian companies to de-risk themselves?
  • where is India in its ambition to become globally preferred destination, especially from reshoring perspective (MNC executives can talk about the company preferences while selecting manufacturers / suppliers)?
  • what more is required from policy intervention perspective?


  • Mr. Gaurav Suchak, Head of Supply Chain, Zydus Cadila
  • Mr. Swapn Malpani, Joint President and Global Head Supply, Cipla
  • Mr. Sreenivas Rao, Global Head Supply Chain, Sun Pharma
  • Mr. Prasad Deshpande, Global Head Supply Chain, ‎Biocon Ltd.


  • Mr. Saikat Ghosh, Associate Partner, EY

Accelerating the journey from primary importers to large scale exporters

An area that came into focus during COVID 19 was the urgent need for sufficient medical supplies, rapid diagnostics, and surveillance. This session deliberates on the current position and future potential of India MedTech sector:

  • What has been restricting the growth of the Indian MedTech industry?
  • India has been good in frugal innovation as also evidenced by some innovative COVID diagnostics: can this be a potential opportunity for India?
  • Digital therapeutics: with the current strength in IT, could this be another area to aspire for?
  • When and how will India foray into complex and innovative medical devices? How has the PLI scheme helped? What more does the industry need?


  • Mr. Jayesh Ranjan IAS, Principal Secretary, Industries & Commerce Dept., Government of Telangana
  • Dr. S Eswara Reddy, Joint Drugs Controller, Central Drugs Standard Control Organization
  • Mr. Madan R Krishnan, Vice President & Managing Director, Medtronic India
  • Mr. Suresh Vazirani, Chairman and Managing Director, Transasia Bio-Medicals Ltd.
  • Dr. Shravan Subramanyam, President & CEO, GE Healthcare India & South Asia
  • Mr. Bhargav Kotadia, Managing Director, SMT
  • Mr. Rajiv Nath, Managing Director, Hindustan Syringes & Medical Devices Ltd & Forum Coordinator, AiMeD


  • Ms. Ekta Batra, Anchor & Deputy Editor, CNBC TV18

  • Innovating at the intersection of healthcare, technology and finance
  • Promoting affordable and accessible innovation in the healthcare sector
  • Role of start-ups in healthcare sector
  • Means of financing R&D and the power of collaboration


  • Mr. George Bickerstaff, Co-founder and Managing Director, M.M. Dillon & Co., Former CFO, Novartis
  • Dr. Jo Bury, CEO, VIB (Case Study: Flanders Institute of Biotechnology, widely recognized as an established and world-leading knowledge center in life sciences and biotechnology with an excellent reputation in technology transfer)

Fireside Chat between Mr. Satya Nadella, CEO, Microsoft and Mr. KT Rama Rao, Hon’ble Minister for Industries & Commerce, Government of Telangana

Replicating the 'generics' success story

India has established its leadership in the generics market. It is time now for the country to replicate the success in the 'complex generics' and 'biosimilars' market.

  • What level of penetration should India aspire to achieve in the global 'complex generics' and 'biosimilars' space?
  • Where is India at present?
  • What has limited India's position in the biosimilars space despite being the first country to launch biosimilars in the domestic market?
  • What investments and enablers are required to achieve the future growth ambition (e.g. policy and regulatory approval support, collaboration with academia for R&D, etc.)?


  • Mr. KT Rama Rao, Hon’ble Minister for Industries & Commerce, Government of Telangana
  • Mr. Amitabh Kant, Chief Executive Officer, NITI Aayog, Government of India
  • Ms. Kiran Mazumdar Shaw, Executive Chairperson, Biocon Ltd.
  • Dr. Swati Piramal , Vice-Chairperson, Piramal Group
  • Mr. Nilesh Gupta, Managing Director, Lupin Ltd.
  • Mr. Sriram Shrinivasan, India Life Sciences Leader, EY


  • Ms. Shereen Bhan, Managing Editor, CNBC-TV18

COVID led to some significant changes in the way R&D could be done and approved globally and in India

  • What are some of the best practices in drug/vaccine development and regulatory approvals during COVID time (e.g. gov-industry-academia collaboration, strong collaboration within the industry, use of technology in expediting R&D, fast regulatory approvals - gov collaborating as an enabler in the true sense, etc.)?
  • What are the learning in the area of drug repurposing and how can the process be made more efficient and productive?
  • How could these learnings become a new normal and not just best practices to manage emergency situations (discuss the efforts and initiatives by the gov and the industry in this direction)?
  • How can the R&D advancement help India establish its global presence as true innovators (i.e. launch of NCEs, NBEs, cell & gene therapy, etc.)? What further investments and enablers are required for achieving success in these areas?

Coffee Table Conversation:

  • Dr. Andrew Plump, President R&D, Takeda
  • Dr. Lutz Hegemann, Group Head of Corporate Affairs and Global Health, Novartis


  • Ms. Archana Shukla, Associate Editor Healthcare, CNBC-TV18